(Q43469799)

23 November 2017

CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression (English)

1 reference

23 November 2017

1 reference

1 reference

acute myeloid leukemia

1 reference

Y Saito

1

1 reference

23 November 2017

S Nakahata

2

1 reference

23 November 2017

N Yamakawa

3

1 reference

23 November 2017

K Kaneda

4

1 reference

23 November 2017

E Ichihara

5

1 reference

23 November 2017

A Suekane

6

1 reference

23 November 2017

K Morishita

7

1 reference

23 November 2017

11 March 2011

1 reference

23 November 2017

1 reference

23 November 2017

25

1 reference

23 November 2017

6

1 reference

23 November 2017

921-931

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.36

23 November 2017

0 references

cites work

Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Activity of alemtuzumab in patients with CD52-positive acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

The CD52 antigen and development of the CAMPATH antibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Structural motifs involved in human IgG antibody effector functions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

The characterisation of the lymphoma cell line U937, using comparative genomic hybridisation and multi-plex FISH.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Alterations in the colorectal carcinoma gene and protein in a novel human myeloid leukemia cell line with trisomy 18 established from overt leukemia after myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Expression of CD52 in peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Primary structure of CD52.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Different glycoforms of the human GPI-anchored antigen CD52 associate differently with lipid microdomains in leukocytes and sperm membranes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.36

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.36

1 reference

Dimensions Publication ID

23 November 2017

0 references

1 reference